A pancreatic mass is any abnormal growth or area of tissue found in or on the pancreas, the organ behind your stomach that produces digestive enzymes and insulin. Not every pancreatic mass is cancer. An estimated 24 to 50% of incidentally discovered pancreatic masses turn out to be malignant, while another 24 to 47% are considered pre-malignant or potentially malignant. The rest are benign. What happens next depends entirely on the type, size, and location of the mass.
Types of Pancreatic Masses
Pancreatic masses fall into three broad categories: solid tumors, cystic lesions (fluid-filled sacs), and inflammatory masses that mimic tumors on imaging.
The most common malignant solid tumor is pancreatic ductal adenocarcinoma, which accounts for the vast majority of pancreatic cancers. Its incidence is increasing by roughly 0.5% per year. Far less common solid masses include neuroendocrine tumors (about 2% of detected pancreatic tumors), lymphoma (extremely rare, about 0.2% of pancreatic tumors), and metastases from cancers elsewhere in the body.
Cystic lesions range from completely benign to potentially cancerous. Serous cystadenomas are generally benign. Mucinous cystic neoplasms carry significant malignant potential. Intraductal papillary mucinous neoplasms (IPMNs) are among the most common cystic findings, and about 30% of resected IPMNs contain invasive cancer. The risk varies dramatically by subtype: those involving the main pancreatic duct are far more dangerous, with over 95% showing either high-grade precancerous changes or invasive cancer at surgery. Side-branch IPMNs carry a much lower annual risk of becoming invasive, around 2% per year.
Inflammatory masses, particularly autoimmune pancreatitis, are a well-known mimic of pancreatic cancer. This rare form of chronic pancreatitis causes immune-driven inflammation that can create a mass visible on scans, complete with jaundice and other symptoms that look identical to cancer. Uneven fatty deposits in the pancreas can also mimic a tumor on CT scans.
Symptoms Depend on Location
The pancreas has three main sections: the head (near the bile duct), the body, and the tail. Where a mass sits determines what you feel, and how quickly it gets noticed.
Masses in the head of the pancreas tend to press on the bile duct early, causing progressive jaundice (yellowing of the skin and eyes), dark urine, pale stools, and itching. Because jaundice is hard to ignore, head tumors are often caught earlier. Masses in the body or tail typically don’t block the bile duct, so they grow silently. Pain and weight loss are the more common presenting symptoms, and by the time those appear, the disease is often locally advanced or has already spread. This difference in timing is a major reason body and tail cancers carry a worse prognosis overall.
How a Pancreatic Mass Is Diagnosed
Most pancreatic masses are first spotted on a CT scan or MRI, sometimes during workup for symptoms and sometimes incidentally during imaging for an unrelated issue. On contrast-enhanced scans, pancreatic adenocarcinoma typically appears as a dark (low-density) area compared to the surrounding pancreatic tissue. But some cancers blend in with normal tissue, and some benign conditions look suspicious, making diagnosis more complex than a single scan.
MRI offers additional tools. Fat-suppressed imaging sequences are particularly good at spotting small tumors. A technique called MRCP can visualize the pancreatic duct system and look for the “duct penetrating sign,” where the pancreatic duct passes through the mass. This sign suggests an inflammatory process rather than cancer, because tumors tend to block or cut off the duct rather than allowing it to pass through. In autoimmune pancreatitis, the duct may partially narrow but rarely dilates downstream, which helps distinguish it from a true malignancy.
When imaging is inconclusive, endoscopic ultrasound with fine-needle aspiration (EUS-FNA) is the standard next step. A thin, flexible scope is passed through the mouth into the stomach or small intestine, where an ultrasound probe guides a needle directly into the mass to collect tissue. For diagnosing adenocarcinoma specifically, this procedure has a sensitivity of about 80% and a specificity of 92%, meaning it’s very reliable when it finds cancer but can occasionally miss it.
A blood marker called CA 19-9 is sometimes measured, but it cannot diagnose pancreatic cancer on its own. Levels rise with many digestive cancers and some non-cancerous conditions. Some people don’t produce CA 19-9 at all, even when cancer is present. Its main value is in tracking how a known cancer responds to treatment and watching for recurrence after surgery.
Distinguishing Cancer From Autoimmune Pancreatitis
Because autoimmune pancreatitis can look nearly identical to cancer on imaging and even cause the same symptoms, getting this distinction right is critical. The diagnosis relies on a combination of imaging patterns, blood tests for a specific antibody called IgG4, tissue biopsy, involvement of other organs, and response to steroid treatment.
A key clinical test is a short course of corticosteroids. Autoimmune pancreatitis responds dramatically to steroids, with the mass shrinking within weeks. If there’s no improvement after four to six weeks, cancer needs to be ruled out. Tissue biopsy often remains necessary, because the consequences of treating cancer as inflammation, or vice versa, are severe.
What Determines Treatment Options
For masses confirmed as malignant, the single most important factor is whether the tumor can be surgically removed. This classification hinges on how much the tumor involves nearby blood vessels.
A tumor is considered resectable when it hasn’t encased major arteries or veins. Borderline resectable means the tumor touches or partially wraps around key blood vessels but may still be removable with advanced surgical techniques, sometimes after chemotherapy to shrink it first. Locally advanced means the tumor extensively wraps around major arteries or blocks veins without a feasible option for reconstruction, making surgery unlikely to succeed. Pain caused by nerve invasion is also a red flag: even if imaging suggests the tumor is removable, significant pain can indicate the disease has spread beyond what scans show.
Survival rates for pancreatic cancer reflect how critical early detection is. When the cancer is caught while still localized to the pancreas, the five-year survival rate is 44%. Once it has spread to nearby tissues or lymph nodes, that drops to 17%. For cancer that has spread to distant organs, the five-year survival rate is 3%. Across all stages combined, the overall five-year survival rate is 13%.
Cystic Masses and Monitoring
Not all pancreatic masses require immediate treatment. Many cystic lesions, particularly small side-branch IPMNs and serous cystadenomas, are monitored over time with periodic imaging rather than removed surgically.
Features that raise concern in a cystic mass include a cyst larger than 3 centimeters, thickened or enhanced cyst walls, solid nodules within the cyst, dilation of the main pancreatic duct to 10 millimeters or more, and new-onset diabetes developing alongside the cyst. Obstructive jaundice or clearly enhanced solid components within the cyst are considered high-risk findings that typically prompt surgical evaluation. The development of diabetes early in the course of a cystic lesion is an underappreciated warning sign for malignancy.
When a cystic mass is surgically removed because of worrisome features, cancer is actually found in only about 30% of those cases. This means the majority of surgeries for concerning cysts are ultimately performed on pre-cancerous or benign lesions, which reflects the intentionally cautious approach to a disease where late detection is so dangerous.